2024³â 12¿ù 28ÀÏ Åä¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Kioxia Installs Solar Power Generation Systems at Kitakami and Yokkaichi Plants in Japan in Major New Sustainability Initiative

´º½ºÀÏÀÚ: 2023-02-02



TOKYO-- February 02, 2023 -- Kioxia Group is increasing the usage of renewable energy by installing large-scale solar power generation systems for the first time at its Kitakami Plant and Yokkaichi Plant. Installed on the rooftop of flash memory fabrication facilities, the new solar power systems will be the largest of their kind at any semiconductor plant in Japan. With a total generating capacity of about 7.5 megawatts (MW), the new solar power systems are expected to generate about 7,600 megawatt hours (MWh) of electricity annually for Kioxia and reduce carbon dioxide emissions by about 3,200 tons per year. With the new solar power systems, we will accelerate our efforts to address climate change, one of the key objectives of our management strategy.

The solar power generation system at Fab1 of our Kitakami Plant became operational recently while the system at Fab6 of our Yokkaichi Plant will be operational in June of this year.

Kioxia Group has set the goal of sourcing 100% of its energy from renewable sources by FY2040, including solar power. We will continue to address climate change proactively and aim to develop sustainably for the benefit of society.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Biocodex Strengthens Supply Chain Resilience with Kinaxis
PHC Live Cell Metabolic Analyzer (LiCellMo) Receives 2024 Innovation Award from The Analytical Scientist
IRIS2 lifts off as European Commission and SpaceRISE sign contract in Brussels
HistoSonics Edison¢ç Histotripsy System Treats First Pancreatic Tumor Patients in GANNON Trial
Novotech Named a Fierce CRO Award Winner in the Excellence
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
The Next Gen of AI Awaits, GIGABYTE Sets the Benchmark for HPC at CES 2025

 

SpaceRISE Signs Concession Contract to Deliver Europe¡¯s IRIS©÷ Connec...
Boomi Boosts Data Management Capabilities With Acquisition of Modern D...
Korean Robotaxi Startup Sonnet.AI Secures Level 4 Autonomous Shuttles ...
KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Valid...
CHMP Recommends Approval of Galderma¡¯s Nemolizumab for Moderate-to-Se...
BrightPath Bio and Cellistic Announced Process Development and Manufac...
Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engi...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚÇ¥±â 'ãæÚ¤ó¢'
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á
¾Ë¶ã°Ç¼³, »óÇ¥µî·Ï ¿Ï·á
Á¸Â÷´åÄÄ, ±Û²Ã º¯°æ »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..